<div><p>There&#8217;s no de&#173;fin&#173;i&#173;tive proof yet that <a href="https://endpts.com/gsk-pitches-in-on-the-global-rd-campaign-to-develop-a-vaccine-to-counter-a-likely-coronavirus-pandemic/">Gilead&#8217;s remde&#173;sivir</a> works as a treat&#173;ment for 2019-nCov, but re&#173;searchers in Chi&#173;na clear&#173;ly con&#173;sid&#173;er it promis&#173;ing enough to have ap&#173;plied for a patent on its use to com&#173;bat the coro&#173;n&#173;avirus virus out&#173;break stem&#173;ming from Wuhan.</p>
<p>Amid world&#173;wide vig&#173;i&#173;lance over what many fear is be&#173;com&#173;ing a pan&#173;dem&#173;ic, sci&#173;en&#173;tists from the Wuhan In&#173;sti&#173;tute of Vi&#173;rol&#173;o&#173;gy and Na&#173;tion&#173;al En&#173;gi&#173;neer&#173;ing Re&#173;search Cen&#173;ter for the Emer&#173;gency Drug said they have test&#173;ed a to&#173;tal of sev&#173;en drugs in vit&#173;ro &#8212; and found remde&#173;sivir and the malar&#173;ia treat&#173;ment chloro&#173;quine most ef&#173;fec&#173;tive against the nov&#173;el coro&#173;n&#173;avirus.</p>
<p>In a <a href="http://www.whiov.cas.cn/kyjz_105338/202002/t20200204_5497136.html" target="_blank" rel="nofollow noopener noreferrer">state&#173;ment</a>, the in&#173;sti&#173;tu&#173;tions al&#173;so dis&#173;closed that they filed a patent ap&#173;pli&#173;ca&#173;tion on Jan&#173;u&#173;ary 21, days be&#173;fore Gilead first an&#173;nounced it&#8217;s <a href="https://endpts.com/gilead-dusts-off-a-failed-ebola-drug-as-coronavirus-spreads-exelixis-boasts-positive-ph-i-ii-data/">dust&#173;ing off</a> the nu&#173;cle&#173;o&#173;side ana&#173;log &#8212; which failed to make the cut as an Ebo&#173;la drug &#8212; to test against the new virus.</p><p class="epn_article_ad" id="rakia_within_article_4098653554"></p><p>While ex&#173;perts have in&#173;di&#173;cat&#173;ed that a patent is un&#173;like&#173;ly to be grant&#173;ed, the move high&#173;lights grow&#173;ing con&#173;fi&#173;dence in remde&#173;sivir in the midst of a glob&#173;al race to hunt an&#173;ti&#173;bod&#173;ies and ther&#173;a&#173;pies for 2019-nCoV, for which there is no ap&#173;proved treat&#173;ment. The high&#173;ly con&#173;ta&#173;gious virus has killed more than 490, most&#173;ly in Chi&#173;na.</p>
<p>The up&#173;date al&#173;so comes as the FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-takes-significant-step-coronavirus-response-efforts-issues-emergency-use-authorization-first" target="_blank" rel="nofollow noopener noreferrer">is&#173;sued</a> its first Emer&#173;gency Use Au&#173;tho&#173;riza&#173;tion (EUA) since the De&#173;part&#173;ment of Health and Hu&#173;man Ser&#173;vices de&#173;clared a pub&#173;lic health emer&#173;gency in the US on Jan&#173;u&#173;ary 31. The EUA means that the 2019-nCoV di&#173;ag&#173;nos&#173;tic pan&#173;el that&#8217;s been in use at CDC labs can now be used at any CDC-qual&#173;i&#173;fied lab across the coun&#173;try.</p>
<p>Gilead &#8212; which has been in a patent <a href="https://endpts.com/gilead-claims-truvada-patents-in-hhs-complaint-are-invalid/">dis&#173;pute</a> with the US gov&#173;ern&#173;ment over its HIV fran&#173;chise &#8212; didn&#8217;t an&#173;swer di&#173;rect&#173;ly whether it knew about the patent fil&#173;ing be&#173;fore the an&#173;nounce&#173;ment or what it thought about the Chi&#173;nese re&#173;searchers&#8217; grounds.</p>
<blockquote><p>Gilead in&#173;vent&#173;ed remde&#173;sivir and has patent&#173;ed it in Chi&#173;na, in&#173;clud&#173;ing fil&#173;ing patent ap&#173;pli&#173;ca&#173;tions for use on coro&#173;n&#173;avirus&#173;es. We are aware of re&#173;ports of the Wuhan In&#173;sti&#173;tute for Vi&#173;rol&#173;o&#173;gy&#8217;s patent ap&#173;pli&#173;ca&#173;tion. Our fo&#173;cus at this time, is on rapid&#173;ly de&#173;ter&#173;min&#173;ing the po&#173;ten&#173;tial for remde&#173;sivir as a treat&#173;ment for 2019-nCoV and ac&#173;cel&#173;er&#173;at&#173;ing man&#173;u&#173;fac&#173;tur&#173;ing in an&#173;tic&#173;i&#173;pa&#173;tion of po&#173;ten&#173;tial fu&#173;ture sup&#173;ply needs.</p></blockquote>
<p>Af&#173;ter US doc&#173;tors <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2001191" target="_blank" rel="nofollow noopener noreferrer">re&#173;port&#173;ed</a> us&#173;ing remde&#173;sivir as part of the reg&#173;i&#173;men for the first do&#173;mes&#173;tic case of 2019-nCoV, Gilead said it&#8217;s work&#173;ing with Chi&#173;nese au&#173;thor&#173;i&#173;ties to start a ran&#173;dom&#173;ized con&#173;trolled tri&#173;al.</p>
<p>Nine tri&#173;als are al&#173;ready un&#173;der&#173;way to eval&#173;u&#173;ate dif&#173;fer&#173;ent com&#173;bi&#173;na&#173;tions of al&#173;ready ap&#173;proved an&#173;tivi&#173;rals and cor&#173;ti&#173;cos&#173;teroids, Bio&#173;Cen&#173;tu&#173;ry <a href="https://www.biocentury.com/article/304368" target="_blank" rel="nofollow noopener noreferrer">not&#173;ed</a>, in&#173;clud&#173;ing HIV drugs such as <a href="https://endpts.com/abbvie-donates-1m-of-the-hiv-drug-that-china-is-now-using-to-contain-coronavirus-outbreak/">Ab&#173;b&#173;Vie&#8217;s</a> Kale&#173;tra/Alu&#173;via and Gilead&#8217;s De&#173;scovy.</p>
<p>Remde&#173;sivir, on the oth&#173;er hand, is an ex&#173;per&#173;i&#173;men&#173;tal com&#173;pound that&#8217;s been test&#173;ed in hu&#173;man tri&#173;als. In a Q4 earn&#173;ings call, Gilead CEO Daniel O&#8217;Day in&#173;di&#173;cat&#173;ed that it may be de&#173;ployed as an emer&#173;gency treat&#173;ment. In re&#173;sponse to a ques&#173;tion about man&#173;u&#173;fac&#173;tur&#173;ing prepa&#173;ra&#173;tions in the event that they need to scale up pro&#173;duc&#173;tion quick&#173;ly, he had this to re&#173;port:</p>
<blockquote><p>In terms of man&#173;u&#173;fac&#173;tur&#173;ing, our team has re&#173;al&#173;ly been work&#173;ing night and day, it&#8217;s been very im&#173;pres&#173;sive to watch this team over the past cou&#173;ple of weeks re&#173;al&#173;ly ramp up to the ex&#173;tent that we can. Our ca&#173;pac&#173;i&#173;ty is go&#173;ing up every day. We&#8217;re look&#173;ing at all the op&#173;tions we have ex&#173;pect&#173;ing to be pre&#173;pared for what may come.</p>
<p>Ob&#173;vi&#173;ous&#173;ly we are wait&#173;ing for da&#173;ta, both in vit&#173;ro and then in peo&#173;ple to en&#173;sure that the drug ac&#173;tu&#173;al&#173;ly works. And it&#8217;s im&#173;por&#173;tant just for every&#173;one to keep that in mind that this is still in&#173;ves&#173;ti&#173;ga&#173;tion&#173;al and we are still wait&#173;ing for more da&#173;ta to know. But at risk, we are in&#173;vest&#173;ing pret&#173;ty heav&#173;i&#173;ly to make sure that we&#8217;re pre&#173;pared as best as we can.</p></blockquote>
<p>Around the same time, some in vit&#173;ro da&#173;ta were be&#173;ing <a href="https://www.nature.com/articles/s41422-020-0282-0" target="_blank" rel="nofollow noopener noreferrer">pub&#173;lished</a> on Na&#173;ture as a let&#173;ter to the ed&#173;i&#173;tor.</p>
<p>&#8220;No&#173;tably, two com&#173;pounds remde&#173;sivir (EC50&#8201;=&#8201;0.77&#8201;&#956;M; CC50&#8201;&gt;&#8201;100&#8201;&#956;M; SI&#8201;&gt;&#8201;129.87) and chloro&#173;quine (EC50&#8201;=&#8201;1.13&#8201;&#956;M; CC50&#8201;&gt;&#8201;100&#8201;&#956;M, SI&#8201;&gt;&#8201;88.50) po&#173;tent&#173;ly blocked virus in&#173;fec&#173;tion at low-mi&#173;cro&#173;mo&#173;lar con&#173;cen&#173;tra&#173;tion and showed high SI,&#8221; they wrote.</p>
<p>Giv&#173;en its po&#173;ten&#173;tial, the Wuhan In&#173;sti&#173;tute of Vi&#173;rol&#173;o&#173;gy said in a state&#173;ment, it&#8217;s ap&#173;plied for a patent in Chi&#173;na and plans to dis&#173;trib&#173;ute to oth&#173;er coun&#173;tries via the Patent Co&#173;op&#173;er&#173;a&#173;tion Treaty. But should &#8220;the rel&#173;e&#173;vant over&#173;seas com&#173;pa&#173;ny&#8221; be will&#173;ing to con&#173;tribute to the out&#173;break con&#173;trol, they would tem&#173;porar&#173;i&#173;ly sus&#173;pend ex&#173;er&#173;cise of their patent rights.</p>
<p>But ex&#173;perts in&#173;ter&#173;viewed by <a href="https://m.21jingji.com/article/20200205/herald/5aff07af6c82edc3d81453b77f6fcae2.html" target="_blank" rel="nofollow noopener noreferrer">lo&#173;cal me&#173;dia</a> point out that the ap&#173;pli&#173;ca&#173;tion may not go through. Not on&#173;ly does Gilead hold the foun&#173;da&#173;tion&#173;al patent to the drug, but it al&#173;so ap&#173;plied for one to cov&#173;er remde&#173;sivir&#8217;s use in coro&#173;n&#173;avirus&#173;es back in 2016 &#8212; which didn&#8217;t spec&#173;i&#173;fy but could ar&#173;guably in&#173;clude this new strain.</p>


<p class="epn_tag_box">
    
</p>
</div>